DETeCD-ADRD guideline provides a structured, multi-tiered approach for diagnosing and evaluating suspected Alzheimer’s Disease and Related Dementias (ADRD) in primary care, emphasizing patient-centered communication, validated cognitive assessments, and individualized laboratory and imaging tests. It also outlines a stepwise diagnostic disclosure process, ensuring patients and caregivers receive clear information abo...

Low-density lipoprotein cholesterol (LDL-C) below 70 mg/dL was linked to a 26% lower risk of dementia and a 28% lower risk of Alzheimer’s disease-related dementia (ADRD) compared to levels above 130 mg/dL. Levels below 55 mg/dL further reduced risk by 18%. Among those with LDL-C <70 mg/dL, statin use reduced dementia risk by 13% and ADRD risk by 12%, highlighting lipid management’s role in dementia prevention.

A new study found that even mild kidney insufficiency (60–89 mL/min/1.73 m²) doubled 1-year mortality risk (HR 2.18) & was linked to a higher neutrophil-lymphocyte ratio (NLR) at admission in ST-segment elevation myocardial infarction (STEMI) patients. Inflammation mediated 1.7% of this association. Integrating eGFR & NLR into the risk model improved mortality prediction accuracy from 73% to 80% (C-index, 0.799).

The BOSS trial found no survival benefit from routine surveillance endoscopy over symptom-driven endoscopy for Barrett’s esophagus. Among 3,453 patients followed for 12.8 years, overall & cancer-specific survival were comparable (HR 0.95, HR 1·01). The incidence & stage of esophageal adenocarcinoma at diagnosis showed no difference, suggesting symptom-guided endoscopy as a less invasive option for low-risk patients.